<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02647099</url>
  </required_header>
  <id_info>
    <org_study_id>921-2014-7074</org_study_id>
    <nct_id>NCT02647099</nct_id>
  </id_info>
  <brief_title>Adjuvant Low Dose Aspirin in Colorectal Cancer</brief_title>
  <acronym>ALASCCA</acronym>
  <official_title>A Randomized Double-blind Placebo-controlled Study With ASA Treatment in Colorectal Cancer Patients With Mutations in the PI3K Signaling Pathway</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anna Martling</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Uppsala University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ALASCCA is a randomized, parallel group, double blind, multicenter, placebo-controlled,&#xD;
      biomarker-based study of adjuvant treatment with low dose aspirin in patients with colorectal&#xD;
      cancer. Hypothesis is that patients diagnosed with colorectal cancer and somatic mutations in&#xD;
      PI3K pathway can significantly improve survival if treated with low dose aspirin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with colorectal cancer clinical stage I-III will be screened for inclusion at the&#xD;
      time of tumor surgery (at time of routine patient visit before elective surgery or&#xD;
      postoperatively within 12 weeks in case of emergency procedure or if screening was missed&#xD;
      preoperatively). After inclusion and when surgery is performed, patients with PIK3 mutations&#xD;
      and stage II and III tumors will be randomized to receive 160 mg aspirin or placebo orally.&#xD;
&#xD;
      Last date for randomization and start of treatment is 12 weeks postoperatively. The treatment&#xD;
      can be administered alone or in combination with adjuvant chemotherapy. The choice of any&#xD;
      adjuvant chemotherapy is made by the Investigator and should follow the guidelines in the&#xD;
      National Care Program. The treatment will be administered for 3 years. There will be a&#xD;
      follow-up period for two years. Outside the trial, the patient will be treated according to&#xD;
      standard care at the site.&#xD;
&#xD;
      A phone contact will be made 3 months after the randomization visit and thereafter every 6th&#xD;
      month. The patients will also visit the site 6 months after randomization and thereafter&#xD;
      every 6th month i.e. the patients will be in contact with the site every 3rd month. There&#xD;
      will also be a visit/phone contact at the end of the follow-up period.&#xD;
&#xD;
      The primary objective is to determine whether adjuvant treatment with 160mg ASA once daily&#xD;
      for 3 years can improve time to recurrence in participants with colorectal cancer with&#xD;
      somatic alternations in the PI3K singling pathway.&#xD;
&#xD;
      UPDATE: New dimensional analysis and power calculation, 19th October 2020:&#xD;
&#xD;
      A total of 3900 patients will be screened in order to include 300 patients with PIK3CA (Exon&#xD;
      9 and 20) mutated tumors in each treatment arm (Group A). With an estimated 10 % drop-out&#xD;
      rate, 150 patients will be randomized in each arm. This also includes approximately 15 % of&#xD;
      the patients that will be excluded due to tumor stage 1.&#xD;
&#xD;
      An additional 300 patients with mutations in other PI3K pathway genes PIK3CA (other than exon&#xD;
      9 and 20), PIK3R1 or PTEN will also be randomized in each arm and will be treated as a&#xD;
      separate group in the analyses (Group B). With an estimated 10 % drop-out rate, 150 patients&#xD;
      will be randomized in each arm.&#xD;
&#xD;
      Patients already treated with ASA at inclusion will be included in an observation group.&#xD;
&#xD;
      An interim analysis will be made on safety i.e incidence and type of serious bleeding&#xD;
      complication grade &gt; 1 after 12 months. An independent safety data monitoring committee will&#xD;
      be responsible for evaluating and follow-up of the safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 7, 2016</start_date>
  <completion_date type="Anticipated">August 2026</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time To Recurrence (TTR)</measure>
    <time_frame>3 years</time_frame>
    <description>Defined as local recurrence, distant metastases or death from same cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events (AE)</measure>
    <time_frame>1 year and 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One tablet acetylsalicylic acid (ASA) 160 mg, orally once daily for three years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One tablet placebo orally once daily for three years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid</intervention_name>
    <arm_group_label>Aspirin</arm_group_label>
    <other_name>ASA, aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Tumor with somatic alterations in PIK3CA, PIK3R1 or PTEN&#xD;
&#xD;
          -  Colon or rectal cancer tumor stage II-III&#xD;
&#xD;
          -  Radical surgery according to surgeon and pathologist&#xD;
&#xD;
          -  Karnofsky performance status ≥60%&#xD;
&#xD;
          -  Platelets ≥ 100 x 109 / L&#xD;
&#xD;
          -  Clean Colonoscopy or Computed Tomography (CT) colon within 3 months preoperatively or&#xD;
             postoperatively but before randomization&#xD;
&#xD;
          -  Patient able to swallow tablets&#xD;
&#xD;
          -  Patient able to understand and sign written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hereditary colorectal cancer linked to familial colonic polyposis or Lynch syndrome&#xD;
&#xD;
          -  Inflammatory bowel disease (Crohn's disease or ulcerative colitis)&#xD;
&#xD;
          -  Distant metastases&#xD;
&#xD;
          -  Other cancers (excluding colorectal cancer or other skin cancer than melanoma) within&#xD;
             3 years from screening&#xD;
&#xD;
          -  Known bleeding diathesis (such as hemophilia)&#xD;
&#xD;
          -  Concomitant antiplatelet therapy (eg clopidrogrel or ticlopidine) or anticoagulant&#xD;
             therapy (warfarin or low molecular weight heparin). Post-operative treatment with low&#xD;
             molecular weight heparin must be withdrawn before administration of study treatment&#xD;
&#xD;
          -  Active gastritis or peptic ulcer, or significant surgical post-op bleeding, within the&#xD;
             previous three months assessed at screening and randomization&#xD;
&#xD;
          -  Ongoing regular use of corticosteroids, Nonsteroidal Anti-Inflammatory Drug (NSAID)&#xD;
&#xD;
          -  Uncontrolled hypertension according to Investigator's judgment&#xD;
&#xD;
          -  Clinically significant liver impairment according to Investigators judgment&#xD;
&#xD;
          -  Existing renal failure according to Investigator's judgment. Renal failure with&#xD;
             decreased creatinine clearance &lt;60 should lead to consultation with a nephrologist.&#xD;
&#xD;
          -  Significant medical illness that would interfere with study participation&#xD;
&#xD;
          -  Pregnancy or breastfeeding females&#xD;
&#xD;
          -  Known allergy to NSAIDs or ASA&#xD;
&#xD;
          -  Current participation in another clinical trial that will be in conflict with the&#xD;
             present study&#xD;
&#xD;
          -  Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude,&#xD;
             inability to return for subsequent visits) and/or otherwise considered by the&#xD;
             Investigator to be unlikely to complete the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Martling, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Martling, Professor</last_name>
    <phone>+46851770000</phone>
    <email>anna.martling@ki.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sabine Sullow-Barin, Nurse</last_name>
    <phone>+46851770000</phone>
    <email>sabine.sullow-barin@ki.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Randers Regional Hospital</name>
      <address>
        <city>Randers</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viborg Region Hospital</name>
      <address>
        <city>Viborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jorvi Hospital</name>
      <address>
        <city>Espoo</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meilahti Tower Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Norway</name>
      <address>
        <city>Tromsø</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Falu Hospital</name>
      <address>
        <city>Falun</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eastern Hospital</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ryhov Hospital</name>
      <address>
        <city>Jönköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Blekinge Hospital (Karlskrona-Karlshamn)</name>
      <address>
        <city>Karlskrona</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karlstad Central Hospital</name>
      <address>
        <city>Karlstad</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sunderby Hospital</name>
      <address>
        <city>Luleå</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mora Hospital</name>
      <address>
        <city>Mora</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vrinnevi Hospital</name>
      <address>
        <city>Norrköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skaraborg Hospital</name>
      <address>
        <city>Skövde</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Capio S:t Göran Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Danderyd Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ersta Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Martling, Professor</last_name>
      <phone>+46851770000</phone>
      <email>anna.martling@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sundsvall Regional Hospital (Sundsvall-Härnösand)</name>
      <address>
        <city>Sundsvall</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northern Älvsborg County Hospital</name>
      <address>
        <city>Trollhättan</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Umeå</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Västerås Central Hospital</name>
      <address>
        <city>Västerås</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ystad Hospital</name>
      <address>
        <city>Ystad</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 5, 2016</study_first_submitted>
  <study_first_submitted_qc>January 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <last_update_submitted>January 31, 2021</last_update_submitted>
  <last_update_submitted_qc>January 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Anna Martling</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Aspirin</keyword>
  <keyword>PI3K signaling pathway</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

